Fig. 3: S2172 treatment downregulated the stemness-associated genes in GSC1228. | Cancer Gene Therapy

Fig. 3: S2172 treatment downregulated the stemness-associated genes in GSC1228.

From: Novel pharmacologic inhibition of lysine-specific demethylase 1 as a potential therapeutic for glioblastoma

Fig. 3

A mRNA expression of stem cell marker genes following 96 h treatment of GSC1228 with S2172 (5 μM). The y-axis indicates the expression change relative to DMSO-treated cells. Error bar indicates the SD. *P < 0.05. B Left panel, western blot analysis of MYC, Nestin, and SOX2 after treatment of GSC1228 with either DMSO or S2172 (5 μM) for 96 h. β-actin (ACTB) was used as the loading control. Right panel, Quantification of band signal intensities from the western blot. C mRNA expression of the differentiation marker gene, GFAP, following treatment of GSC1228 with S2172 (5 μM) for 96 h. The y-axis indicates the expression change relative to DMSO-treated cells. Error bar indicates the SD. D PARP cleavage ratio after treatment of GSC1228, GSC222, and GSC316 with S2172 (5 μM). The ratio was calculated by dividing the cleaved-PARP band intensity by the full length-PARP band intensity. Error bar indicates the SD. *P < 0.05. E Representative Western blot results of RAPR after treatment of GSC1228, GSC222, and GSC316 with either DMSO or S2172 (5 μM) for 96 h. The full length-PARP band (106 kDa) and cleaved PARP band (89 kDa) are shown. β-actin (ACTB) was used as the loading control. n = 4.

Back to article page